Tandem Diabetes Care (TNDM) Net Cash Flow (QoQ) (2013 - 2026)
Tandem Diabetes Care (TNDM) Net Cash Flow (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.39 Bn | 174.10 Bn | 6.27 Bn |
| 2 | Stryker | 128.38 Bn | 125.50 Bn | 3.81 Bn |
| 3 | Medtronic | 107.68 Bn | 98.46 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.98 Bn | 66.53 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.81 Bn | 44.13 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.53 Bn | 26.25 Bn | 1.98 Bn |
| 7 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.78 Bn | 26.20 Bn | - |
| 9 | Koninklijke Philips | 25.34 Bn | 22.21 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.16 Bn | 585.31 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,575.30% |
| Dec 31, 2025 | -109.49% |
| Sep 30, 2025 | 205.23% |
| Jun 30, 2025 | 164.74% |
| Mar 31, 2025 | -176.43% |
| Dec 31, 2024 | 662.65% |
| Sep 30, 2024 | 120.01% |
| Jun 30, 2024 | -2,312.92% |
| Mar 31, 2024 | 102.52% |
| Dec 31, 2023 | 57.95% |
| Sep 30, 2023 | -1,616.13% |
| Jun 30, 2023 | 107.35% |
| Mar 31, 2023 | -194.76% |
| Dec 31, 2022 | 429.61% |
| Sep 30, 2022 | -57.74% |
| Jun 30, 2022 | -5.28% |
| Mar 31, 2022 | 154.48% |
| Dec 31, 2021 | -399.45% |
| Sep 30, 2021 | 162.00% |
| Jun 30, 2021 | -185.01% |